Business Context and Reporting Period
This Form 8-K Current Report from Cartesian Therapeutics, Inc. (RNAC) covers events occurring on October 29, 2025. The filing addresses significant changes to the Company's Board of Directors and corporate governance structure.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance and personnel changes.
Material Changes
- Resignation of Chairman: Carrie S. Cox resigned from the Board of Directors, effective immediately, due to her appointment as Executive Chair of another publicly-traded company. She previously served as Chairman of the Board, Chairman of the Compensation Committee, and a member of the Audit Committee.
- Board Appointments:
- Carsten Brunn, Ph.D. appointed as Chairman of the Board (no additional compensation).
- Patrick Zenner, M.B.A. appointed as Lead Independent Director (compensation provided per the Non-Employee Director Compensation Program).
- Kemal Malik, M.B.B.S. appointed as Chairman of the Compensation Committee (compensation provided per the Non-Employee Director Compensation Program).
- Bylaws Amendment: The Board approved an amendment and restatement of the Company's Bylaws to include references to the position of Lead Independent Director.
Guidance, Outlook, and Risks
The filing states that Ms. Cox's resignation was not the result of any disagreement with the Company regarding operations, policies, or practices. No financial guidance, outlook, or new risk factors were disclosed in this report. A press release regarding Dr. Brunn's appointment was issued on October 30, 2025.
Investor Verification Checklist
- Verify the new composition of the Board of Directors and committee assignments.
- Review the attached Amended and Restated Bylaws (Exhibit 3.2) for specific governance changes.
- Confirm the compensation arrangements for the newly appointed Lead Independent Director and Compensation Committee Chair.
- Check for any subsequent filings regarding the appointment of a new member to the Audit Committee, as Ms. Cox's departure created a vacancy.